Efficacy and safety of febuxostat in patients with hyperuricemia and gout

Therapeutic Advances in Musculoskeletal Disease

Volumn 3, Issue 5, 2011, Pages 245-253

  Garcia Valladares, Ignacio ^a   Khan, Tahir ^a   Espinoza, Luis R ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

efficacy profile; febuxostat; gout; hyperuricemia; safety profile

Indexed keywords

ALLOPURINOL; COLCHICINE; CREATININE; FEBUXOSTAT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ABDOMINAL PAIN; ARTHRALGIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CREATININE CLEARANCE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GOUT; HEADACHE; HEART INFARCTION; HUMAN; HYPERURICEMIA; KIDNEY DISEASE; LIVER DISEASE; LIVER FUNCTION TEST; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

EID: 84857467025     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X11416405     Document Type: Review

References (49)

1. Becker M.A. Kisicki J. Khosravan R. Wu J. Mulford D. Hunt B. et al (2004) Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleos Nucleot Nucleic Acids 23: 1111–1116.
2. Becker M.A. Schumacher H.R. Jr Espinoza L.R. Wells A.F. MacDonald P. Lloyd E. et al (2010) The urate-lowering efficacy and safety of febuxostat in the treatment of hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 12: R63–R63.
3. Becker M.A. Schumacher H.R. MacDonald P.A. Lloyd E. Lademacher C. (2009) Clinical efficacy and safety of successful long-term urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 36: 1273–1282.
4. Becker M.A. Schumacher H.R. Jr Wortmann R.L. MacDonald P.A. Eustace D. Palo W.A. et al (2005 a) Febuxostat compared with allopurinol in patients with hyperuricemia. N Engl J Med 353: 2450–2461.
5. Becker M.A. Schumacher H.R. Jr Wortmann R.L. MacDonald P.A. Palo W.A. Eustace D. et al (2005 b) Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: a twenty-eight day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 52: 916–923.
6. Burns C.M. Wortmann R.L. (2011) Gout therapeutics: new drugs for an old disease. Lancet 377: 165–177.
7. Chao J. Terkeltaub R. (2009) A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep 11: 135–140.
8. Chiou W.K. Wang M.H. Huang D.H. Chiu H.T. Lee Y.J. Lin J.D. (2010) The relationship between serum uric acid level and metabolic syndrome: differences by sex and age in Taiwanese. J Epidemiol 20: 219–224.
9. Choi H.K. Ford E.S. Li C. Curhan G. (2007) Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination survey. Arthritis Rheum 57: 109–115.
10. Choi H.K. Zhu Y. Mount D.B. (2010) Genetics of gout. Curr Opin Rheumatol 22: 144–151.
11. Dehghan A. Kottgen A. Yang Q. Hwang S.J. Kao W.L. Rivadeneira F. et al (2008) Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 372: 1953–1961.
12. Dubost, J.J., Mathieu, S. and Soubrier, M. (2011) Treatment of gout. Rev Med Interne [Epub ahead of print].
13. Edwards N.L. (2009) Febuxostat: a new treatment for hyperuricemia in gout. Rheumatology 48(Suppl. 2): ii15–ii19.
14. Feig D.I. (2009) Uric acid: a novel mediator and marker of risk in chronic kidney disease? Curr Opin Nephrol Hypertens 18: 526–530.
15. Feig D.I. Soletsky B. Johnson R.J. (2008) Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300: 924–932.
16. Ghaemi-Oskouie F. Shi Y. (2011) The role of uric acid as an endogenous danger signal in immunity and inflammation. Curr Rheumatol Rep 13: 160–166.
17. Grabowski B. Khosravan R. Wu J.T. Vernillet L. Lademacher C. (2010) Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase. Br J Clin Pharmacol 70: 57–64.
18. Gray C.L. Walters-Smith N.E. (2011) Febuxostat for treatment of chronic gout. Am J Health Syst Pharm 68: 389–398.
19. Jansen T.L. Richette P. Perez-Ruiz F. Tausche A.K. Guerne P.A. Punzi L. et al (2010) International position paper on febuxostat. Clin Rheumatol 29: 835–840.
20. Khosravan R. Grabowski B.A. Mayer M.D. Wu J.T. Joseph-Ridge N. Vernillet L. (2006 a) The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics and safety of febuxostat, a novel non-purine selective inhibitor of xanthine oxidase. J Clin Pharmacol 46: 88–102.
21. Khosravan R. Grabowski B.A. Wu J.T. Joseph-Ridge N. Vernillet L. (2006 b) Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clin Pharmacokinet 45: 821–841.
22. Khosravan R. Grabowski B. Wu J.T. Joseph-Ridge N. Vernillet L. (2008 a) Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. Br J Pharmacol 65: 355–363.
23. Khosravan R. Kukulka M.J. Wu J.T. Joseph-Ridge N. Vernillet L. (2008 b) The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel non-purine selective inhibitor of xanthine oxidase. J Clin Pharmacol 48: 1014–1024.
24. Lawrence R.C. Felson D.T. Helmick G.G. Arnold L.M. Choi H. Deyo R.A. et al (2008) Estimates of the prevalence of arthritis and other rheumatic diseases in the United States. Part II. Arthritis Rheum 58: 26–35.
25. Love B.L. Barrons R. Veverka A. Snider K.M. (2010) Urate-lowering therapy for gout: focus on febuxostat. Pharmacotherapy 30: 594–608.
26. Lustberg M.E. (2006) Febuxostat versus allopurinol for gout. N Engl J Med 354: 1532–1533.
27. Martinon F. Petrilli V. Mayor A. Tardivel A. Tschopp J. (2006) Gout-associated uric acid crystals activate the NALP 3 inflammasome. Nature 440: 237–241.
28. Mayer M.D. Khosravan R. Vernillet L. Wu J.T. Joseph-Ridge N. Mulford D.J. (2005) Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther 12: 22–34.
29. Mazzali M. Kanbay M. Segal M.S. Shafiu M. Jalal D. Feig D.I. et al (2010) Uric acid and hypertension: cause or effect? Curr Rheumatol Rep 12: 108–117.
30. Nakaya, I., Namikoshi, T., Tsuruta, Y., Nakata, T., Shibagaki, Y., Onishi, Y. et al. (2011) Management of asymptomatic hyperuricemia. Nephrology [Epub ahead of print].
31. Nuki G. Simkin P.A. (2006) A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther 8(Suppl. 1): S1–S5.
32. Okamoto K. Eger B.T. Nishino T. Kondo S. Pai E.F. Nishino T. (2003) An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem 278: 1848–1855.
33. Osada Y. Tsuchimoto M. Fukushima H. Takahashi K. Kondo S. Hasegawa M. et al (1993) Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur J Pharmacol 241: 183–188.
34. Reinders M.K. Jansen T.L. (2010) Management of hyperuricemia in gout: focus on febuxostat. Clin Interv Aging 5: 7–18.
35. Riches P.L. Wright A.F. Ralston S.H. (2009) Recent insights into the pathogenesis of hyperuricemia and gout. Hum Mol Genet 18: R177–R184.
36. Reinders M.K. Haagsma C. Jansen T.L. van Roon E.N. Delsing J. van de Laar M.A. et al (2009) A randomized controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout. Ann Rheum Dis 68: 892–897.
37. Schlesinger N. Dalbeth N. Perez-Ruiz F. (2009) Gout–what are the treatment options? Expert Opin Pharmacother 10: 1319–1328.
38. Schumacher H.R. Jr Becker M.A. Lloyd E. MacDonald P.A. Lademacher C. (2009) Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 48: 188–194.
39. Schumacher H.R. Jr Becker M.A. Wortmann R.L. MacDonald P.A. Hunt B. Streit J. et al (2008) Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 59: 1540–1548.
40. Singh J.A. (2010) Advances in gout: some answers, more questions. Arthritis Res Ther 12: 136–136.
41. Stevenson M. Pandor A. (2011) Febuxostat for the management of hyperuricemia in patients with gout: a NICE single technology appraisal. Pharmaco Economics 29: 133–140.
42. Sundy J.S. (2010) Progress in the pharmacology of gout. Curr Opin Rheumatol 22: 188–193.
43. Terkeltaub R. (2010) Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 6: 30–38.
44. Weaver A.L. (2008) Epidemiology of gout. Cleve Clin J Med 75(Suppl 5): S9–S12.
45. Whelton A. MacDonald P.A. Zhao L. Hunt B. Gunawardhana L. (2011) Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol 17: 7–13.
46. Wortmann R.L. Schumacher H.R. Jr (2005) Monosodium urate deposition arthropathy part II: treatment and long-term management of patients with gout. Adv Studies Med 5: 183–194.
47. Wortmann R.L. MacDonald P.A. Hunt B. Jackson R.L. (2010) Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther 32: 2386–2397.
48. Yamamoto T. Moriwaki Y. Fujimura Y. Takahashi S. Tsutsumi Z. Tsutsui T. et al (2000) Effect of TEI-6720, a xanthine oxidase inhibitor, on the nucleoside transport in the lung cancer cell line A549. Pharmacology 60: 34–40.
49. Zhang W. Doherty M. Bardin T. Pascual E. Borskova V. Conagham P. et al (2006) EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 65: 1312–1324.